A cheap, well-tolerated plant compound the body largely converts to a related compound before anything reaches the blood. Support is narrow: modified forms modestly ease leg swelling, aching and cramping where veins drain poorly, and haemorrhoid bleeding and itching. Kidney, gut, brain and lifespan findings come from animals. The calculation differs for those already managing swollen legs. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Ferritin | 50–125 ng/mL (men), 40–100 ng/mL (women) | Detects the non-heme iron absorption effect before anaemia develops |
| Haemoglobin | 13.5–15.0 g/dL (men), 12.5–14.0 g/dL (women) | Confirms whether reduced iron absorption has become clinically relevant |
| Platelet count | 175,000–350,000 per microlitre | Baseline for the bleeding-risk assessment, since rutin suppresses platelet aggregation |
| Alanine aminotransferase | 10–25 U/L (men), 10–20 U/L (women) | Liver enzyme; confirms the conjugation route handling rutin's metabolites is intact |
| Estimated glomerular filtration rate | Above 90 mL/min/1.73 m² | Kidney filtration estimate; slower clearance raises metabolite exposure |
| Thyroid-stimulating hormone | 0.5–2.0 mIU/L | Detects any drift from flavonoid inhibition of thyroid enzymes |
| High-sensitivity C-reactive protein | Below 0.8 mg/L | General inflammation marker; the plausible target of any anti-inflammatory effect |
| Fasting glucose | 75–86 mg/dL | Tracks the metabolic claim that human trials have so far failed to confirm |
| Ankle circumference | No established target; track change from the individual's own baseline in millimetres | The one endpoint the venous trials reliably moved |
Cadence: Baseline panel before starting, repeated at 12 weeks, then every 6–12 months. Those on anticoagulants add a clotting-time check within two weeks of starting; those on thyroid replacement add a thyroid-stimulating hormone check at eight weeks.